Dual Src and EGFR inhibition in combination with gemcitabine in advanced pancreatic cancer: phase I results: A phase I clinical trial

Summary Pancreatic adenocarcinoma remains a major therapeutic challenge, as the poor (

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Investigational new drugs 2018-06, Vol.36 (3), p.442-450
Hauptverfasser:	Cardin, Dana B., Goff, Laura W., Chan, Emily, Whisenant, Jennifer G., Dan Ayers, G., Takebe, Naoko, Arlinghaus, Lori R., Yankeelov, Thomas E., Berlin, Jordan, Merchant, Nipun
Format:	Artikel
Sprache:	eng
Schlagworte:	Aged Antineoplastic Agents - adverse effects Antineoplastic Agents - therapeutic use Antineoplastic Combined Chemotherapy Protocols - adverse effects Antineoplastic Combined Chemotherapy Protocols - therapeutic use CA-19-9 Antigen - metabolism Deoxycytidine - adverse effects Deoxycytidine - analogs & derivatives Deoxycytidine - therapeutic use Diffusion Magnetic Resonance Imaging ErbB Receptors - antagonists & inhibitors Female Gemcitabine Humans Male Medicine Medicine & Public Health Middle Aged Oncology Pancreatic Neoplasms - diagnostic imaging Pancreatic Neoplasms - drug therapy Pharmacology/Toxicology Phase I Studies Protein Kinase Inhibitors - adverse effects Protein Kinase Inhibitors - therapeutic use src-Family Kinases - antagonists & inhibitors
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Summary Pancreatic adenocarcinoma remains a major therapeutic challenge, as the poor (
ISSN:	0167-6997 1573-0646
DOI:	10.1007/s10637-017-0519-z